argenx SE (ARGX) Stock Price & How to Invest

argenx SE is a Netherlands-based, globally operating immunology company that trades in the US as a Nasdaq ADR. Its lead product, Vyvgart and the subcutaneous Vyvgart Hytrulo (efgartigimod), is an FcRn blocker that lowers pathogenic IgG antibodies. It is approved for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), plus primary immune thrombocytopenia in Japan, and reached roughly 19,000 patients on treatment by the end of 2025.

The investment picture is a classic biotech growth profile: revenue is compounding quickly (about $4.15 billion in 2025 global product net sales, up roughly 90% year over year, with Q1 2026 sales near $1.3 billion), the company turned profitable and holds a large cash cushion, and the pipeline aims to expand efgartigimod into new autoimmune indications while advancing next-generation FcRn and complement candidates. Against that, the market cap of roughly $47 billion prices in substantial future success, so the shares carry the volatility typical of a single-franchise-led biotech.

argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. The FcRn field is crowding: UCB (rozanolixizumab, zilucoplan), Johnson & Johnson (nipocalimab), and Immunovant (batoclimab and IMVT-1402) are all competing in overlapping indications, and AstraZeneca's complement inhibitors address parts of the same market. Pipeline setbacks or missed Phase 3 readouts could sharply reset expectations given the high valuation. As an ADR of a European company, holders also carry currency and cross-listing considerations. Biotech shares like ARGX tend to be volatile around clinical and regulatory events.

22 analysts publish price targets on ARGX, averaging $1079.55 against a $853.82 price as of August 2026, or +26.4%. The published targets run from $770.00 to $1350.00, a moderate spread, and the ratings split 21 buy, 2 hold, 1 sell. Over the last six months there have been 9 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ARGX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on argenx SE. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Vyvgart franchise momentum. Vyvgart posted its 17th consecutive quarter of growth in Q1 2026, with sales near $1.3 billion (up 63% year over year) and roughly 19,000 patients on treatment. The most optimistic published target, $1350.00, assumes this works close to its best case.

The case against. argenx revenue is heavily concentrated in one molecule, efgartigimod, so any safety signal, pricing pressure, or slowdown in gMG and CIDP uptake would weigh directly on the whole company. The most pessimistic target, $770.00, is roughly what ARGX is worth if this bites instead.

Read the full bull and bear case on ARGX, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see argenx SE's investor relations page or your broker.

• Revenue (2025 product net sales): ~$4.15B
• Revenue growth (2025 YoY): ~90%
• Q1 2026 net sales: ~$1.3B (+63% YoY)
• Q1 2026 profit: ~$366M
• Cash and current financial assets: ~$4.9B
• Market cap: ~$47B

argenx trades as a high-growth, richly valued biotech rather than on trailing earnings multiples, with the roughly $47 billion market cap reflecting expectations for continued Vyvgart expansion and pipeline success. The company is now profitable and self-funding, a meaningful shift from the cash-burning profile common to development-stage biotech. Figures are approximate and reflect data available around May 2026.

If you want ARGX exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses ARGX naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to ARGX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ARGX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (BBH, IBB), which spreads the position across many companies. Or build it into a focused thematic portfolio, so ARGX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ARGX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

argenx is a fast-growing FcRn-focused immunology company where the investment case rests on Vyvgart uptake and pipeline expansion against a rich valuation.

Whether ARGX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ARGX a buy or a sell?, and where the stock could go from here in the ARGX stock forecast.

For income investors, whether ARGX pays a dividend and how the payout looks is covered in does ARGX pay a dividend? And to weigh ARGX against a peer, read the full side-by-side comparisons: ARGX vs VRTX and ARGX vs REGN.